Get the Stockscreener App
4.3029
1.60%
-0.0771
X 4 Pharmaceuticals Inc stock is traded at $4.3029, with a volume of 33,087.
It is down -1.60% in the last 24 hours and up +15.55% over the past month.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
See More
Previous Close:
$4.38
Open:
$4.22
24h Volume:
33,087
Relative Volume:
0.07
Market Cap:
$406.99M
Revenue:
$35.11M
Net Income/Loss:
$-79.20M
P/E Ratio:
-0.9922
EPS:
-4.3367
Net Cash Flow:
$-88.62M
1W Performance:
+5.90%
1M Performance:
+15.55%
6M Performance:
+16.17%
1Y Performance:
+33.02%
1-Day Range:
$4.19
$4.38
1-Week Range:
$4.05
$4.50
52-Week Range:
$1.35
$4.83
X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile
Name
X 4 Pharmaceuticals Inc
Sector
Industry
Phone
857-529-8300
Address
61 NORTH BEACON STREET, BOSTON, MA
Compare XFOR vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XFOR
X 4 Pharmaceuticals Inc
|
4.315 | 413.12M | 35.11M | -79.20M | -88.62M | -4.3367 |
VRTX
Vertex Pharmaceuticals Inc
|
427.12 | 108.54B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
719.11 | 75.59B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
797.07 | 50.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.89 | 40.45B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
310.22 | 32.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-09-26 | Initiated | Guggenheim | Buy |
| Dec-05-25 | Resumed | Stifel | Buy |
| Dec-12-23 | Downgrade | B. Riley Securities | Buy → Neutral |
| Aug-30-23 | Resumed | B. Riley Securities | Buy |
| Dec-22-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-12-22 | Initiated | Piper Sandler | Overweight |
| Dec-23-19 | Initiated | Oppenheimer | Outperform |
| Dec-18-19 | Initiated | ROTH Capital | Buy |
| Dec-09-19 | Upgrade | Citigroup | Neutral → Buy |
| Dec-05-19 | Initiated | B. Riley FBR | Buy |
| Jun-07-19 | Initiated | Stifel | Buy |
| Jun-05-19 | Initiated | Cowen | Outperform |
View All
X 4 Pharmaceuticals Inc Stock (XFOR) Latest News
CapEx per share of X4 Pharmaceuticals, Inc. – FWB:48Q0 - TradingView
EBIT per share of X4 Pharmaceuticals, Inc. – FWB:48Q0 - TradingView
X4 pharmaceuticals incmay offer up to $300 million of common stock, preferred stock, debt securities, warrants, and/or unitsSEC filing - marketscreener.com
X4 Pharmaceuticals (NASDAQ: XFOR) files $300M shelf; $75M ATM with Jefferies - Stock Titan
X4 Pharmaceuticals, Inc. Q1 2026 Financial Results and Forward-Looking Statements – Quarterly Report Highlights - Minichart
X4 Pharmaceuticals (XFOR) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
X4 Pharmaceuticals: Q1 Earnings Snapshot - KING5.com
X4 Pharmaceuticals Reports Positive Updates on 4WARD Phase 3 Trial and European Commission Approval for XOLREMDI - Quiver Quantitative
EU authorizes first WHIM syndrome treatment as X4 trial nears enrollment - Stock Titan
X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewswire
EU approves XOLREMDI as X4 Pharmaceuticals (NASDAQ: XFOR) reports Q1 loss - Stock Titan
NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA - ACCESS Newswire
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis on May 4, 2026 - Business Wire
MSN Money - MSN
Processa (PCSA) CAO Wendy Guy buys 1,748 shares in open-market trade - Stock Titan
Seven new Xenon hires get stock awards priced at $56.04 - Stock Titan
Rhythm Pharmaceuticals Announces IMCIVREE® (Setmelanotide) Granted Marketing Authorization by European Commission for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity - The Manila Times
Europe authorizes first drug for patients with relentless hunger - Stock Titan
XFOR Stock Price, Quote & Chart | X4 PHARMACEUTICALS INC (NASDAQ:XFOR) - ChartMill
Ionis (NASDAQ: IONS) EVP sells 1,626 shares under Rule 10b5-1 plan - Stock Titan
Fierce Biotech Layoff Tracker 2026: Autolus decreases headcount by 13%; Replimune reduces staff - Fierce Biotech
X4 Pharmaceuticals (XFOR) Stock: Directional Bias Review | Q4 2025: Earnings Beat EstimatesCrowd Trend Signals - Newser
$1.9B deal gives Chiesi first oral, on-demand hereditary angioedema treatment - Stock Titan
X4 Pharmaceuticals gets EU approval for WHIM syndrome drug By Investing.com - Investing.com Canada
X4 Pharmaceuticals Announces European Commission Approval of XOLREMDI® (Mavorixafor), the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union - The Manila Times
A rare immune disorder gets its first approved treatment across Europe - Stock Titan
Layoff Tracker: Novartis cuts hit New Jersey again, affecting 60 employees - BioSpace
China SXT Pharmaceuticals (SXTC) Co-CEO reports indirect Class B stake - Stock Titan
X4 Pharmaceuticals Inc expected to post a loss of 20 cents a shareEarnings Preview - TradingView
ET Exclusive | Sun Pharma set to acquire Organon for $12.5 bn, its biggest till date - The Economic Times
Recursion Pharmaceuticals (NASDAQ: RXRX) director sells 40K shares under plan - Stock Titan
ROKU (Roku Inc.) tops Q4 2025 EPS estimates by a wide margin, shares rise nearly 4 percent in today’s session.Trending Stock Ideas - Xã Thanh Hà
Is X4 Pharmaceuticals (XFOR) stock a solid choice for investors | Q4 2025: Earnings Beat Estimates - Cổng thông tin điện tử tỉnh Lào Cai
Liquidia Corp.: Prime Candidate For A Takeout By Large Pharma (LQDA) - Seeking Alpha
Tax-driven RSU share sale by KalVista (KALV) CCO Nicole Sweeny - Stock Titan
Tax-related share sale by KalVista (KALV) CEO after RSU vesting - Stock Titan
Can BMY's Growth Portfolio Counter Legacy Drugs Decline in Q1? - TradingView
Is ANIP Stock Undervalued at 10x Forward Earnings and $93 Target? - TradingView
Xenon Pharmaceuticals Reports Positive Phase 3 X-TOLE2 Study Results for Azetukalner in Focal Onset Seizures at AAN 2026 - Quiver Quantitative
Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results - GlobeNewswire
X4 Pharmaceuticals (XFOR) Stock: Next Quarter (Institutional Demand) 2026-04-18Crowd Entry Points - Cổng thông tin điện tử tỉnh Lào Cai
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Ionis (NASDAQ: IONS) director sells 5,000 shares under Rule 10b5-1 plan - Stock Titan
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Insider Sell: How correlated is X4 Pharmaceuticals Inc to the S P5002026 Breakouts & Breakdowns & Weekly High Potential Alerts - baoquankhu1.vn
EPS Watch: How does X4 Pharmaceuticals Inc score in quality rankings2026 Outlook & Risk Managed Investment Strategies - baoquankhu1.vn
Aug Setups: What is the long term forecast for X4 Pharmaceuticals Inc stock - baoquankhu1.vn
Is AMRX Stock Undervalued? Sales Multiple, Target, Upside - TradingView — Track All Markets
Setup Watch: Is X4 Pharmaceuticals Inc stock a value trapQuarterly Performance Summary & Low Drawdown Momentum Ideas - baoquankhu1.vn
Leading Companies Reinforcing Their Presence in the C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market - openPR.com
Director at Adial (NASDAQ: ADIL) receives 9,185 restricted shares - Stock Titan
X 4 Pharmaceuticals Inc Stock (XFOR) Financials Data
Revenue
Net Income
Cash Flow
EPS
X 4 Pharmaceuticals Inc Stock (XFOR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Baldry Mark | Chief Commercial Officer |
May 16 '25 |
Buy |
2.48 |
1,032 |
2,561 |
25,337 |
5.78%
0.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):